

Special Issue

Recent Advances in the Field of Metastatic Renal Cell Carcinoma Research—from Biology to Predictive Biomarkers towards Personalised Medicine

Message from the Guest Editors

Renal cell carcinoma (RCC) is a malignancy with an increasing incidence in developed countries. The management of metastatic RCC (mRCC) has been markedly changing in recent years, and significant progress has been made in the systemic treatment of metastatic RCC (mRCC), leading to improvements in the survival and quality of life of patients. Tyrosine kinase inhibitors (TKIs) blocking angiogenesis and immunotherapy in the form of immune checkpoint inhibitors (ICIs) represent the most commonly used agents, as well as various combination regimens in the form of ICI+ICI or ICI+TKI, which have become a standard of care in the first-line treatment of mRCC. Although these novel regimens achieve excellent treatment responses, this treatment entails a wide range of side effects and there is no doubt that a single therapy cannot suit every patient with mRCC. In mRCC, relevant predictive biomarkers at the molecular level are still not available; only prognostic models are used (MSKCC, IMDC), but their value is limited from a predictive point of view.

Guest Editors

Dr. Ondřej Fiala

1. Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
2. Laboratory of Cancer Treatment and Tissue Regeneration, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic

Dr. Radka Vaclavikova

1. Toxicogenomics Unit, National Institute of Public Health, 100 42 Prague 10, Czech Republic
2. Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 323 00 Pilsen, Czech Republic

Deadline for manuscript submissions

closed (1 June 2023)



Cells

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed



mdpi.com/si/117635

Cells
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cells@mdpi.com

[mdpi.com/journal/
cells](https://mdpi.com/journal/cells)





Cells

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed



[mdpi.com/journal/
cells](https://mdpi.com/journal/cells)



About the Journal

Message from the Editorial Board

Cells has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

Editors-in-Chief

Dr. Alexander E. Kalyuzhny

Dental Basic Sciences, University of Minnesota, 308 Harvard St. SE,
Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch

Biotech Research & Innovation Centre, The University of Copenhagen,
Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cell Biology) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).